Trial reportNature communications2022
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
Open access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 66 citations in OpenAlex.
- ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer.The oncologist · 2026Trial
- An Accessible Approach to Molecular and Biomarker Testing for Risk Stratification in Oral Cavity Squamous Cell Carcinoma.Head and neck pathology · 2026Article
- Comprehensive Genomic and Transcriptomic Characterization of MTAP Loss across Advanced Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Observational
- Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.JTO clinical and research reports · 2026Article
- Prevalence of heterozygous and homozygous 9p21 deletions in human cancer: a tissue microarray study on 4,999 tumors from 125 different tumor types.Molecular medicine (Cambridge, Mass.) · 2026Article
- Metabolic vulnerabilities in pleural mesothelioma.Oncogenesis · 2026Review
- Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases.bioRxiv : the preprint server for biology · 2026Article
- Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies.NPJ precision oncology · 2026Article
- MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.Cancer research · 2026Review
- HER2 and urothelial carcinoma: current understanding and future directions.Nature reviews. Urology · 2026Review
- Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma.Frontiers in oncology · 2026Article
- Glioblastoma zebrafish Avatars guide therapeutic decisions in a patient with gliosarcoma: a case report.Communications medicine · 2025Article
- MTAP-Null Tumors: A Comprehensive Review on Synthetic Vulnerabilities and Therapeutic Strategies.Cells · 2025Review
- Review
- ThebioRxiv : the preprint server for biology · 2025Article
- Resilience and Vulnerabilities of Tumor Cells under Purine Shortage Stress.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Acquired MTAP Loss Following Entrectinib Resistance in ROS1-Rearranged NSCLC With CD74 Exon 3-ROS1 Exon 34 Fusion.Thoracic cancer · 2025Article
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- MTAP deficiency is highly homogeneous in advanced, muscle-invasive urothelial carcinoma of the urinary bladder.Scientific reports · 2025Article
- Pitfalls in the evaluation of CDKN2A copy number status in meningioma.Journal of neuro-oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors at 2 institutions in 1 country.
Omar Alhalabi *Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-9658-2206
Jianfeng Chen *Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yuxue Zhang *Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yang Lu *Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-9571-4679
Qi WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0003-0858-9393
Sumankalai RamachandranDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Rebecca Slack TidwellDepartment of Biostatistics,, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0003-3041-8582
Guangchun HanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-9277-2507
Xinmiao YanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jieru MengDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ruiping WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Anh G HoangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Wei-Lien WangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-8809-4424
Jian SongDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Lidia LopezDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Alex Andreev-DrakhlinDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Arlene Siefker-RadtkeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-6328-9599
Xinqiao ZhangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
William F BenedictDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Amishi Y ShahDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-9007-0621
Jennifer WangDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Pavlos MsaouelDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Miao ZhangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Charles C GuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Bogdan CzerniakDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Carmen BehrensDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Luisa SotoDepartment of Translational molecular pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-1253-630X
Vassiliki PapadimitrakopoulouDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jeff LewisDepartment of Biostatistics,, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Waree RinsurongkawongDepartment of Biostatistics,, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Vadeerat RinsurongkawongDepartment of Biostatistics,, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jack LeeDepartment of Biostatistics,, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-5469-9214
Jack RothDepartment of Thoracic and Cardiovascular surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-8955-1313
Stephen SwisherDepartment of Thoracic and Cardiovascular surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-3080-1920
Ignacio WistubaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
John HeymachDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-9068-8942
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-5398-0802
Matthew T CampbellDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0003-1915-4491
Eleni EfstathiouDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Mark TitusDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0002-6365-1711
Thai H HoDivision of Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.ORCID 0000-0003-0023-2939
Jianjun ZhangDepartment of Thoracic, Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID 0000-0001-7872-3477
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. LWang22@mdanderson.org.ORCID 0000-0001-9380-0266
Jianjun GaoDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jgao1@mdanderson.org.ORCID 0000-0001-6138-4472
The University of Texas MD Anderson Cancer Center · USMayo Clinic Hospital · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MTargeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4MEffective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironmentR01CA254988 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAO, JIANJUN · 2021 to 2025
$2.6MDecoding tumor metabolic and immunologic interactions driving racial disparity in African American patients with bladder cancer.R01CA282282 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Jianjun Gao, Nagireddy Putluri · 2023 to 2026
$2.5MNCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA140388NCI NIH HHS R01 CA254988NCI NIH HHS R01 CA282282
Abstract
Methylthioadenosine phosphorylase, an essential enzyme for the adenine salvage pathway, is often deficient (MTAP
Indexed as
Carcinoma, Transitional CellFolic Acid AntagonistsUrinary Bladder NeoplasmsHumansProspective StudiesRetrospective StudiesFolic Acid Antagonists
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.